CN1413743A - Vascular suppository material - Google Patents
Vascular suppository material Download PDFInfo
- Publication number
- CN1413743A CN1413743A CN 02135020 CN02135020A CN1413743A CN 1413743 A CN1413743 A CN 1413743A CN 02135020 CN02135020 CN 02135020 CN 02135020 A CN02135020 A CN 02135020A CN 1413743 A CN1413743 A CN 1413743A
- Authority
- CN
- China
- Prior art keywords
- embolism materials
- analgesic
- novel vascular
- microgranule
- materials
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A noval embolic material for blood vessel is composed of the granular embolic material and antalgic medicine attached onto the embolic material for preventing ischemic pain of target.
Description
The present invention relates to a kind of intervention vascular suppository material.
In the prior art, multiple intervention vascular suppository material has been arranged, mainly contain polyvinyl alcohol (Polyvinyl Alcohol, PVA), gelfoam, surgical thread, stainless steel spring circle, platinum microcoils, taking off property sacculus, alpha-cyanoacrylate (cyanoacrylates), dewatered ethanol, iodized oil, sodium morrhuate etc.Avascular pain often appears in target in clinical use, and patient's postoperative need be injected analgesic or oral analgesic.
The objective of the invention is to provide a kind of novel vascular embolism materials, it solves blood vessel embolism postoperative patient target avascular pain problem effectively, has alleviated patient's misery.
The object of the present invention is achieved like this:
The novel vascular embolism materials, comprise analgesic (1), embolism materials (2), it is characterized in that analgesic (1) be entrained in the embolism materials (2) or analgesic (1) attached on the embolism materials (2), form nutty structure or block structure or linear structure or spring-like structures.
---the analgesic (1) of above-mentioned novel vascular embolism materials can mix with anticarcinogen or other medicines, is entrained in the embolism materials (2) or attached on the embolism materials (2), forms nutty structure or block structure or existing list structure or spring-like structures.
---the embolism materials (2) of above-mentioned novel vascular embolism materials can be the Biodegradable vascular suppository material, as gelfoam, sodium alginate, polyglycolic acid, polylactic acid, Ju diox etc.; Also can be non-Biodegradable vascular suppository material, as metal spring steel ring class: steel rim of spring, Ultimum Ti steel rim of spring, stainless steel spring steel ring, the platinum steel rim of spring of band terylene fiber hair; Macromolecule material particle class: polyvinyl alcohol (Polyvinyl Alcohol, PVA) microgranule, politef microgranule, polyethylene microgranule, polyamine fat microgranule, nylon microgranule etc., perhaps porous material particulate species: POROUS TITANIUM metal particle, porous polyethylene microgranule, porous Teflon microgranule, porous polyethylene alcohol microgranule etc.
---the embolism materials (2) of above-mentioned novel vascular embolism materials can be to develop under the X-ray, also can be that X-ray is nonvisualized.
---the analgesic (1) of above-mentioned novel vascular embolism materials can be that solid-state drug is entrained in the embolism materials (2) or is coated in the embolism materials (2), also can be liquid drug be adsorbed on porous embolism materials (2) micropore (3) in.
---the analgesic (1) of above-mentioned novel vascular embolism materials can be entrained in the embolism materials (2) or attached on the embolism materials (2), discharge gradually by release membranes (4).
The present invention is entrained in analgesic on the Biodegradable vascular suppository material or by slow release method analgesic is coated on the non-biodegradation type vascular suppository material, perhaps analgesic is adsorbed in the micropore of porous non-biodegradation type vascular suppository material, slow release by analgesic, prevented blood vessel embolism postoperative patient target avascular pain problem effectively, alleviated patient's misery, be subjected to the patient and welcome.
Concrete structure of the present invention and operation principle are provided by following examples:
Fig. 1 the present invention's graininess is doped with the structural representation of the Biodegradable novel vascular embolism materials of analgesic.
Fig. 2 the present invention's linear is doped with the structural representation of the Biodegradable novel vascular embolism materials of analgesic.
The bulk of Fig. 3 the present invention is doped with the structural representation of the Biodegradable novel vascular embolism materials of analgesic.
Fig. 3 the present invention's spring-like is doped with the structural representation of the Biodegradable novel vascular embolism materials of analgesic.
Fig. 5 the present invention's graininess micro-porous adsorption has the structural representation of the non-biodegradation type porous novel vascular embolism materials of analgesic.
Fig. 6 the present invention's block micro-porous adsorption has the structural representation of the non-biodegradation type porous novel vascular embolism materials of analgesic.
Fig. 7 the present invention's linear micro-porous adsorption has the structural representation of the non-biodegradation type porous novel vascular embolism materials of analgesic.
Fig. 8 the present invention's ellipsoid shape micro-porous adsorption has the structural representation of the non-biodegradation type porous novel vascular embolism materials of analgesic.
Fig. 9 the present invention's graininess analgesic is attached to the structural representation of non-biodegradation type novel vascular embolism materials.
Figure 10 the present invention's block analgesic is attached to the structural representation of non-biodegradation type novel vascular embolism materials.
Figure 11 the present invention's linear analgesic is attached to the structural representation of non-biodegradation type novel vascular embolism materials.
The analgesic of Figure 12 the present invention's linear band release membranes is attached to the structural representation of non-biodegradation type novel vascular embolism materials.
The analgesic of Figure 13 the present invention's graininess band release membranes is attached to the structural representation of non-biodegradation type novel vascular embolism materials.
The analgesic of Figure 14 the present invention's lump zone release membranes is attached to the structural representation of non-biodegradation type novel vascular embolism materials.
Figure 15 the present invention's analgesic is attached to the structural representation of the helical spring steel ring formula novel vascular embolism materials on the one-level metal coil spring.
Figure 16 the present invention's analgesic is attached to the structural representation of the turriform steel rim of spring formula novel vascular embolism materials on the one-level metal coil spring.
Figure 17 the present invention's analgesic is attached to the structural representation of the novel vascular embolism materials on the one-level metal coil spring.
Figure 18 the present invention's analgesic is attached to the structural representation of the steel rim of spring formula novel vascular embolism materials of the cylinder shape belt terylene fiber hair on the one-level metal coil spring.
Figure 19 the present invention's analgesic is attached to the structural representation of the steel rim of spring formula novel vascular embolism materials of the turriform band terylene fiber hair on the one-level metal coil spring.
Figure 20 the present invention's analgesic is attached to the structural representation of the novel vascular embolism materials on the one-level metal coil spring of band terylene fiber hair.
The fundamental diagram of Figure 21 the present invention's novel vascular embolism materials.
Among the above-mentioned figure: 1 is analgesic, and 2 is embolism materials, and 3 is micropore, and 4 is release membranes, and 5 are the present invention's novel vascular embolism materials, and 6 is conduit, and 7 is blood vessel.
Select for use morphine as analgesic (1), select for use gelfoam, morphine and gelfoam are mixed and made into microsphere, promptly obtained the present invention's Biodegradable novel vascular embolism materials (5) as embolism materials (2).Fig. 1 to Fig. 4.
Select for use morphine as analgesic (1), select for use gelfoam as embolism materials (2), select for use cardiografin as developing agent, morphine, cardiografin, gelfoam are mixed and made into microsphere, promptly obtained the present invention's the novel vascular embolism materials (5) that can develop.Fig. 1 to Fig. 4.
Select for use the dolantin injection as analgesic (1), select for use the porous polyethylene microsphere as embolism materials (2), dolantin is adsorbed in the micropore (3) of porous polyethylene microsphere, has promptly obtained the present invention's the non-biodegradation type novel vascular embolism materials (5) that is adsorbed with analgesic (1).Fig. 5 to Fig. 8.
Analgesic (1) is coated on the non-biodegradation type solid vascular suppository material (2), has promptly obtained the present invention's the non-biodegradation type novel vascular embolism materials (5) that is coated with analgesic (1).Fig. 9 to Figure 11.
Analgesic (1) is coated on the non-biodegradation type solid vascular suppository material (2), as release membranes, also can adopts other release membranes, promptly obtained the present invention's the non-biodegradation type novel vascular embolism materials (5) that has release membranes with porous silicon rubber.Figure 12 to Figure 14.
With recovery temperature is 33 ℃, and diameter is the Ultimum Ti filament winding system one-level helical spring of 0.15mm, then the one-level helical spring is regarded as a thick tinsel, and coiling deuterostrophies spring is through the typing heat treatment.To pull into the one-level helical spring through the deuterostrophies spring behind the typing heat treatment, coat with analgesic and morphine then, promptly obtain the present invention's helical spring type novel vascular embolism materials (5).Figure 15 to Figure 17.
With recovery temperature is 33 ℃, and diameter is the Ultimum Ti filament winding system one-level helical spring of 0.15mm, then the one-level helical spring is regarded as a thick tinsel, and coiling deuterostrophies spring is through the typing heat treatment.To pull into the one-level helical spring through the deuterostrophies spring behind the typing heat treatment, coat with analgesic and morphine then, the terylene fiber is wrapped on the one-level helical spring, has promptly obtained the helical spring type novel vascular embolism materials (5) of the present invention's band terylene fiber hair.Figure 18 to Figure 20.
During clinical use,, select suitable the present invention's novel vascular embolism materials (5) according to the vessel size that will stop up and diseased region.In intervene operation, the present invention's novel vascular embolism materials (5) is injected the blood vessel (7) that will stop up by conduit (6).Because the existence of suppository causes thrombosis and finally blocks blood vessel, reaches the purpose of vascular embolization treatment disease; Along with slowly disengaging of analgesic, can solve the target pain that causes because of ischemia effectively, alleviate the patient suffering, Figure 21.
Claims (6)
1, novel vascular embolism materials, comprise analgesic (1), embolism materials (2), it is characterized in that analgesic (1) be entrained in the embolism materials (2) or analgesic (1) attached on the embolism materials (2), form nutty structure or block structure or linear structure or spring-like structures.
2, according to the described novel vascular embolism materials of claim 1, the analgesic (1) that it is characterized in that the novel vascular embolism materials can mix with anticarcinogen or other medicines, be entrained in the embolism materials (2) or attached on the embolism materials (2), form nutty structure or block structure or existing list structure or spring-like structures.
3,, it is characterized in that the embolism materials (2) of novel vascular embolism materials can be the Biodegradable vascular suppository material, as gelfoam, sodium alginate, polyglycolic acid, polylactic acid, Ju diox etc. according to the described novel vascular embolism materials of claim 1; Also can be non-Biodegradable vascular suppository material, as metal spring steel ring class: steel rim of spring, Ultimum Ti steel rim of spring, stainless steel spring steel ring, the platinum steel rim of spring of band terylene fiber hair; Macromolecule material particle class: polyvinyl alcohol (Polyvinyl Alcohol, PVA) microgranule, politef microgranule, polyethylene microgranule, polyamine fat microgranule, nylon microgranule etc., perhaps porous material particulate species: POROUS TITANIUM metal particle, porous polyethylene microgranule, porous Teflon microgranule, porous polyethylene alcohol microgranule etc.
4, according to the described novel vascular embolism materials of claim 1, the embolism materials (2) that it is characterized in that the novel vascular embolism materials can be to develop under the X-ray, also can be that X-ray is nonvisualized.
5, according to the described novel vascular embolism materials of claim 1, the analgesic (1) that it is characterized in that the novel vascular embolism materials can be that solid-state drug is entrained in the embolism materials (2) or is coated in the embolism materials (2), also can be liquid drug be adsorbed on porous embolism materials (2) micropore (3) in.
6, according to the described novel vascular embolism materials of claim 1, the analgesic (1) that it is characterized in that the novel vascular embolism materials can be entrained in the embolism materials (2) or attached on the embolism materials (2), discharge gradually by release membranes (4).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02135020 CN1413743A (en) | 2002-10-25 | 2002-10-25 | Vascular suppository material |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02135020 CN1413743A (en) | 2002-10-25 | 2002-10-25 | Vascular suppository material |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1413743A true CN1413743A (en) | 2003-04-30 |
Family
ID=4747998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02135020 Pending CN1413743A (en) | 2002-10-25 | 2002-10-25 | Vascular suppository material |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1413743A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012171478A1 (en) | 2011-06-17 | 2012-12-20 | 微创医疗器械(上海)有限公司 | Liquid embolic materials based on collagens and preparation method thereof |
| CN106401298A (en) * | 2016-11-02 | 2017-02-15 | 中山市诺源机械设备科技有限公司 | Lock with high antitheft performance and keys thereof |
| CN115584050A (en) * | 2022-10-26 | 2023-01-10 | 上海七木医疗器械有限公司 | Gelatin sponge, preparation method thereof and embolism material prepared from gelatin sponge |
| WO2023125036A1 (en) * | 2021-12-31 | 2023-07-06 | 神泓医疗科技(上海)有限公司 | Liquid embolism composition and use thereof, medical interventional instrument, and interventional therapy drug |
| WO2023125042A1 (en) * | 2021-12-31 | 2023-07-06 | 神泓医疗科技(上海)有限公司 | Liquid embolic agent, and preparation method therefor and use thereof |
| WO2023125039A1 (en) * | 2021-12-31 | 2023-07-06 | 神泓医疗科技(上海)有限公司 | Liquid embolic agent and preparation method therefor and use thereof |
-
2002
- 2002-10-25 CN CN 02135020 patent/CN1413743A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012171478A1 (en) | 2011-06-17 | 2012-12-20 | 微创医疗器械(上海)有限公司 | Liquid embolic materials based on collagens and preparation method thereof |
| CN106401298A (en) * | 2016-11-02 | 2017-02-15 | 中山市诺源机械设备科技有限公司 | Lock with high antitheft performance and keys thereof |
| WO2023125036A1 (en) * | 2021-12-31 | 2023-07-06 | 神泓医疗科技(上海)有限公司 | Liquid embolism composition and use thereof, medical interventional instrument, and interventional therapy drug |
| WO2023125042A1 (en) * | 2021-12-31 | 2023-07-06 | 神泓医疗科技(上海)有限公司 | Liquid embolic agent, and preparation method therefor and use thereof |
| WO2023125039A1 (en) * | 2021-12-31 | 2023-07-06 | 神泓医疗科技(上海)有限公司 | Liquid embolic agent and preparation method therefor and use thereof |
| CN115584050A (en) * | 2022-10-26 | 2023-01-10 | 上海七木医疗器械有限公司 | Gelatin sponge, preparation method thereof and embolism material prepared from gelatin sponge |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rothen-Weinhold et al. | Injection-molding versus extrusion as manufacturing technique for the preparation of biodegradable implants | |
| Robert et al. | Biocompatibility and resorbability of a polylactic acid membrane for periodontal guided tissue regeneration | |
| DE69633399T2 (en) | EXTENDED RELEASE OF GM-CSF | |
| CN1413743A (en) | Vascular suppository material | |
| Sampath et al. | Preparation and characterization of biodegradable poly (L-lactic acid) gentamicin delivery systems | |
| Ping Ooi et al. | The hydrolytic degradation of polydioxanone (PDSII) sutures. Part I: Morphological aspects | |
| CA2548106A1 (en) | Therapeutic microparticles | |
| JP2011518180A (en) | Methods and compositions for treating post-operative pain comprising clonidine | |
| WO2004105824A1 (en) | A bioabsorbable delivery system | |
| JP2010502732A (en) | Method for treating tendonitis in a subject using an anti-cytokine agent | |
| JPS5912293B2 (en) | Surgical synthetic resin material | |
| JP2004525955A (en) | Controlled transmission of tetracycline compounds and tetracycline derivatives | |
| JP2011518187A (en) | Methods and compositions for treating post-operative pain comprising a local anesthetic | |
| WO2012171478A1 (en) | Liquid embolic materials based on collagens and preparation method thereof | |
| CA2251277A1 (en) | Intra-articular preparation for the treatment of arthropathy | |
| CN2576179Y (en) | Novel blood-vessel embolism material | |
| EP1827524A1 (en) | A method to enhance drug release from a composite material for implantation | |
| CN1682693A (en) | In site gel medicine transfer system for hardening treating angioma and vascular deformity | |
| AU2010305430B2 (en) | Delivery system for sustained release of a calcium -channel blocking agent | |
| EP2076247B1 (en) | A self-gelling tunable drug delivery system | |
| KR101626456B1 (en) | Pharmaceutical composition for pulp revasularization and apexogenesis comprising prolyl Hydroxylase Inhibitor or histone deacetylase inhibitor, and antibiotics, and synthetic polymer nano fiber mesh comprising the same | |
| AU2003299982B2 (en) | Coated particles for sustained-release pharmaceutical administration | |
| Milusheva et al. | Bombyx mori chitosan nanoparticles: synthesis and properties | |
| JP3023471B2 (en) | Internal fixation material for osteosynthesis | |
| WO2019064290A1 (en) | Composition and method for controlled drug release from a tissue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |